A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

Trial Profile

A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Idelalisib (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms Havasu
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 25 Jun 2017 Results analysing safety of first-line idelalisib with rituximab in patients with B-cell chronic lymphocytic leukaemia with 17p deletion, presented at the 22nd Congress of the European Haematology Association.
    • 19 May 2016 Status changed from active, no longer recruiting to discontinued.
    • 30 Apr 2016 This trial was Prematurely ended in Austria and Sweden, according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top